Pandemic & Infectious Disease — 2026-04-20
Global measles continues its resurgence as declining vaccination rates and funding cuts fuel outbreaks worldwide, prompting fresh analysis from the Council on Foreign Relations this week. A Phase 3 trial of two tuberculosis vaccine candidates in India reported limited protection results, while the CDC confirmed that respiratory virus activity across the U.S. remains at very low levels heading into late April. The Lyme disease vaccine pipeline also saw new reporting on Pfizer and Valneva's six-strain candidate, with Drug Topics covering positive Phase 3 data showing 73% efficacy.
Pandemic & Infectious Disease — 2026-04-20
Active Outbreak Tracker
Measles Resurgence — Global
- Status: Active, escalating in multiple regions; CDC tracking Top 10 countries with ongoing outbreaks
- Key Development: Declines in vaccination rates — accelerated by funding cuts — have fueled measles outbreaks worldwide. The Council on Foreign Relations published a major analysis this week asking why measles, once eliminated in many nations, is returning in the U.S. and globally. The piece points to gaps in immunization coverage and reduced public health capacity as primary drivers.
- Response: CDC continues to update its global measles vaccination tracker weekly. Public health officials globally are calling for renewed vaccination campaigns and funding restoration.
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
cdc.gov
Current Outbreaks | Foodborne Outbreaks | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
About the Epidemic Intelligence Service | Epidemic Intelligence Service | CDC
Respiratory Virus Season — United States
- Status: Very low activity nationally; 2025–2026 season winding down
- Key Development: CDC's respiratory illness data channel, updated this week, confirms that COVID-19, flu, and RSV activity are all at very low levels across the U.S. The agency's FluView report for Week 13 (ending April 4, 2026) showed that only 0.3% of deaths that week were attributed to influenza. CDC states it does not anticipate producing additional seasonal outlook updates for the remainder of the 2025–2026 respiratory season.
- Response: CDC continues passive surveillance. No new public health advisories have been issued for respiratory viruses this period.
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
cdc.gov
Current Outbreaks | Foodborne Outbreaks | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
About the Epidemic Intelligence Service | Epidemic Intelligence Service | CDC
Current Foodborne Outbreaks — United States
- Status: Active investigations ongoing; CDC monitoring multiple events
- Key Development: CDC's foodborne outbreak tracker, updated within the past five days, lists active investigations and selected outbreak notices. No single large-scale national event has been flagged this week, but regional clusters are under review.
- Response: CDC's foodborne disease branch is actively publishing outbreak notices and working with state health departments on traceback investigations.
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
cdc.gov
Current Outbreaks | Foodborne Outbreaks | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
About the Epidemic Intelligence Service | Epidemic Intelligence Service | CDC
Vaccine & Treatment Pipeline
-
PreVenTB Vaccine Candidates (multiple developers, Phase 3 India): Two experimental tuberculosis vaccine candidates did not demonstrate efficacy against all forms of TB in a large Phase 3 trial conducted in India (July enrollment to results published this week). The candidates were safe and offered limited protection against more severe forms of TB disease, but fell short of demonstrating broad efficacy. GlobalData epidemiologists project TB cases across 16 major markets to reach 4.5 million by 2033, making these results a significant setback for global TB control.
-
VLA15 / Lyme Disease Vaccine (Pfizer & Valneva): Drug Topics this week reported on the six-valent Lyme disease vaccine's Phase 3 data showing 73% efficacy against confirmed Lyme disease cases, paving the way for regulatory filings in 2026. The vaccine targets people aged five and older. Pfizer has signaled it will seek FDA approval despite a technical miss of the trial's primary statistical goal due to fewer-than-expected cases during the study period.
-
COVID-19 Vaccine Antigen Composition (WHO TAG-CO-VAC): WHO's Technical Advisory Group on COVID-19 Vaccine Composition is actively soliciting data ahead of its May 2026 deliberations on which viral strains next-generation vaccines should target. The group continues monitoring SARS-CoV-2 genetic evolution, immune responses, and real-world vaccine performance against circulating variants.
Expert Analysis
The resurgence of measles globally has drawn sharp attention from infectious disease experts this week. The Council on Foreign Relations, in analysis published within the past seven days, highlights that the root causes are twofold: declining routine vaccination rates and cuts to public health funding that have weakened immunization infrastructure. Many countries that had achieved measles elimination status are now seeing cases again — a development that epidemiologists describe as a preventable reversal. The CFR analysis underscores that measles, which requires approximately 95% population immunity to prevent transmission, is uniquely vulnerable to even modest drops in vaccine uptake.
On the tuberculosis front, results from the PreVenTB Phase 3 trial in India represent a significant setback for the global effort to develop better TB vaccines. The CIDRAP report published this week notes that while both candidates were confirmed safe, neither demonstrated the broad efficacy against all TB forms that health authorities had hoped for. Given that GlobalData projects TB cases to reach 4.5 million annually across major markets by 2033, the failure to secure an effective vaccine keeps one of the world's leading infectious disease burdens without a modern immunization solution. Public health experts caution that the results do not end the pipeline, but push back timelines for any vaccine-based intervention against TB.
Meanwhile, WHO's World Health Day message this year — "Together for health. Stand with science." — reflects ongoing institutional anxiety about science communication and public trust in vaccines and public health institutions. At the WHO level, officials continue to stress that international cooperation and evidence-based policy are foundational to preventing the next pandemic, a theme that has intensified since COVID-19.
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
cdc.gov
Current Outbreaks | Foodborne Outbreaks | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
About the Epidemic Intelligence Service | Epidemic Intelligence Service | CDC
Global Health Security
The Lancet Infectious Diseases journal, recognized this week with a 2026 impact factor of 29.5, continues to prioritize pandemic preparedness, emerging pathogens, antimicrobial resistance, and vaccine effectiveness as its top editorial focus areas — a signal of where the global scientific community is directing its attention and resources in the current threat environment.
WHO's May 2026 COVID-19 vaccine composition deliberations represent a key near-term milestone in global health security governance. The TAG-CO-VAC process — in which WHO solicits data from manufacturers, surveillance networks, and immunology researchers — determines which SARS-CoV-2 strains are incorporated into vaccines for the next season, affecting billions of people worldwide. The open call for data signals that variant surveillance remains active even as COVID-19 hospitalizations are low in many regions.
Pfizer and Valneva's imminent FDA filing for their Lyme disease vaccine candidate marks the first serious regulatory push for a Lyme vaccine in over two decades. If approved, VLA15 would represent a major addition to the U.S. public health toolkit for a disease that infects an estimated 476,000 Americans annually. The regulatory pathway and any FDA advisory committee dates will be closely tracked by infectious disease practitioners throughout 2026.
What to Watch Next
-
WHO May 2026 COVID-19 Vaccine Composition Meeting: WHO's TAG-CO-VAC will convene in May to finalize antigen recommendations for next-generation COVID-19 vaccines. The outcome will directly shape which variants are targeted and influence global manufacturing orders — a decision with significant public health implications as the virus continues to evolve.
-
Lyme Disease Vaccine FDA Filing: Pfizer and Valneva are expected to submit their regulatory application to the FDA for VLA15 in 2026 following strong Phase 3 efficacy data. Watch for an FDA filing announcement and subsequent advisory committee scheduling, which would mark a historic milestone in tick-borne disease prevention.
-
Global Measles Vaccination Gaps: With measles outbreaks intensifying across multiple WHO-tracked countries and funding pressures continuing to strain immunization programs, the trajectory of coverage rates in mid-2026 will determine whether outbreaks expand or are brought under control before peak transmission seasons in affected regions.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
